Hospital pediatrics · 2026
Congenital Cytomegalovirus Testing Following Pennsylvania Hearing-Targeted Screening Legislation.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Coggins Sarah A, Garber Samuel J, Christ Lori A, Drinker Lisa R, Mukhopadhyay Sagori, Puopolo Karen M
Аннотация
BACKGROUND: Congenital cytomegalovirus infection (cCMV) occurs in approximately 1/200 to 1/250 US newborns each year and can cause progressive sensorineural hearing loss. Since 2022, Pennsylvania law mandates cCMV testing for infants who fail newborn hearing screening.
OBJECTIVES: To assess changes in cCMV testing rates and diagnosis before and after Pennsylvania hearing-targeted legislation.
METHODS: Retrospective cohort study of all live births at 3 university-affiliated birth centers. We identified all infants tested for CMV at 21 days of age or younger and analyzed cCMV testing rates in pre- (January 2018-June 2022) and post- (July 2022-December 2024) legislation eras using interrupted time-series analysis. We assessed other clinical signs associated with cCMV testing using standard statistics.
RESULTS: The study cohort included 85 324 infants. Among 54 909 born prelegislation, 3168 (5.8%) had cCMV testing; among 30 415 born postlegislation, 3197 (10.5%) were tested. cCMV testing rates increased significantly among term (by 3.2%) and preterm infants (by 15.5%) at the beginning of the postlegislation era (P = .003 and .001, respectively). Among 5224 infants with hearing-based criteria for screening, CMV testing increased from 36.7% prelegislation to 74.0% postlegislation (P < .001). In the postlegislation period, testing associated with isolated microcephaly increased, but isolated small for gestational age-associated testing decreased. Among 61 infants diagnosed with cCMV, 16 (26.2%) were identified based on hearing criteria alone (2.3/1000 infants prelegislation, 6.0/1000 infants postlegislation, P = .04).
CONCLUSIONS: CMV testing and diagnosis based on hearing criteria alone increased significantly post passage of Pennsylvania hearing-targeted cCMV testing legislation, but infants tested for hearing criteria alone accounted for less than half of identified cCMV cases.
OBJECTIVES: To assess changes in cCMV testing rates and diagnosis before and after Pennsylvania hearing-targeted legislation.
METHODS: Retrospective cohort study of all live births at 3 university-affiliated birth centers. We identified all infants tested for CMV at 21 days of age or younger and analyzed cCMV testing rates in pre- (January 2018-June 2022) and post- (July 2022-December 2024) legislation eras using interrupted time-series analysis. We assessed other clinical signs associated with cCMV testing using standard statistics.
RESULTS: The study cohort included 85 324 infants. Among 54 909 born prelegislation, 3168 (5.8%) had cCMV testing; among 30 415 born postlegislation, 3197 (10.5%) were tested. cCMV testing rates increased significantly among term (by 3.2%) and preterm infants (by 15.5%) at the beginning of the postlegislation era (P = .003 and .001, respectively). Among 5224 infants with hearing-based criteria for screening, CMV testing increased from 36.7% prelegislation to 74.0% postlegislation (P < .001). In the postlegislation period, testing associated with isolated microcephaly increased, but isolated small for gestational age-associated testing decreased. Among 61 infants diagnosed with cCMV, 16 (26.2%) were identified based on hearing criteria alone (2.3/1000 infants prelegislation, 6.0/1000 infants postlegislation, P = .04).
CONCLUSIONS: CMV testing and diagnosis based on hearing criteria alone increased significantly post passage of Pennsylvania hearing-targeted cCMV testing legislation, but infants tested for hearing criteria alone accounted for less than half of identified cCMV cases.